Author:
Cunha Nélia,Fattouh Kinda,Frings Verena,Hernandez-Aragues Ignacio,Stembridge Natasha,Kuonen François
Reference7 articles.
1. Olasz A, Christensen E, Braun R, Foss OA, Dotterud LK. Curettage and multiple needle puncture-assisted methyl aminolaevulinate photodynamic therapy of basal cell carcinoma. Eur J Dermatol 2018; 28: 818–22.
2. Mikolajewska P, Donnelly RF, Garland MJ, et al. Microneedle pre-treatment of human skin improves 5-aminolevulininc acid (ALA)- and 5-aminolevulinic acid methyl ester (MAL)-induced PpIX production for topical photodynamic therapy without increase in pain or erythema. Pharm Res 2010; 27: 2213–20.
3. Sandberg C, Halldin CB, Ericson MB, Larkö O, Krogstad AL, Wennberg AM. Bioavailability of aminolaevulinic acid and methylaminolaevulinate in basal cell carcinomas: a perfusion study using microdialysis in vivo. Br J Dermatol 2008; 159: 1170–6.
4. Mathias SD, Chren MM, Colwell HH, et al. Assessing health-related quality of life for advanced basal cell carcinoma and basal cell carcinoma nevus syndrome: development of the first disease-specific patient-reported outcome questionnaires. JAMA Dermatol 2014; 150: 169–76.
5. Hansson J, Bartley K, Karagiannis T, et al. Assessment of quality of life using Skindex-16 in patients with advanced basal cell carcinoma treated with vismodegib in the STEVIE study. Eur J Dermatol 2018; 28: 775–83.